WRITTEN BY
We are excited to welcome NordicRWE, the first Norwegian company to join the AstraZeneca BioVentureHub at the Gothenburg R&D site.
NordicRWE, an emerging company specializing in real-world evidence (RWE) generation, has officially become a member of AstraZeneca's BioVentureHub, marking an important milestone in the company's journey. NordicRWE's focus on real-world evidence analytics and insights aligns seamlessly with the industry's growing demand for data-driven decision-making. By leveraging Nordic real-world data and advanced analytics and cutting-edge methodologies, NordicRWE is developing solutions that support data-driven drug development.
"We are excited to join the BioVentureHub community, renowned for its collaborative spirit and innovation. This unique opportunity enables us to seek valuable guidance, explore potential collaborations with AstraZeneca R&D, and shape our research programs in Real-World Evidence. Our goal is not only to benefit from the incredible resources within the BioVentureHub, but also to actively contribute to its culture of 'dare to share.' As the first fully dedicated RWE company and the first Norwegian company to join, we are eager to share our expertise and guide the community." Says Christian Jonasson, MSc. Pharm. Ph.D. Research Director, NordicRWE.
“Real World Evidence (RWE) is pivotal in advancing evidence-based medicine, bridging the gap between clinical research and practice. Partnering with stakeholders across the healthcare community to drive evidence-based medicine is crucial in our pursuit of better healthcare outcomes. NordicRWE's dedication to data-driven drug development aligns with our vision. We are looking forward to learn more, collaborate, maximize RWD assets, drive innovation, and to address unmet medical needs."
Nina Mian, Executive Director, Head of Data Science & Advanced Analytics, AstraZeneca
Ulrika Edvardsson, Managing Director AstraZeneca BioVentureHub, comments “We are thrilled to welcome NordicRWE to the BioVentureHub. NordicRWE's entry into the BioVentureHub exemplifies the commitment to fostering a collaborative ecosystem where breakthrough ideas and cutting-edge technologies converge to address unmet medical needs.”
The first Norwegian company in BioVentureHub.
NordicRWE is the first Norwegian company joining the BioVentureHub, and a result of the Memorandum of Understanding signed in December 2023, with the aim to stimulate innovation and further developing the Nordic life science ecosystem. The Memorandum of Understanding was signed between Oslo Cancer Cluster, Oslo Science City and AstraZeneca BioVentureHub.
Read more about the agreement and signing here.
The NordicRWE Team, visitng the BioVentureHub team at AstraZeneca R&D site in Gothenburg.
From the left: Pernilla Isberg Director AZ BioVentureHub, Christian Jonasson and Steinar Thoresen, founders NordicRWE, Robert Roth, Science Director and Ulrika Edvardsson, Managing Director AZ BioVentureHub.
Please read more about NordicRWE here: www.nordicrwe.com/
Read more about NordicRWE on Linkedin: Cllick here.
Read more about the news about the MOU between AZ BioVentureHub and the Norwegian Ecosystem: Click here.
Follow AstraZeneca BioVentureHub on Linkedin: Click here.
Subscribe to the BioVentureHub Newsletter: Sign up here.